文献速递炎症性肠病

综述文章:重视肌肉减少症——炎症性肠病患者肌肉丢失的发病机制、评估与临床影响

Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-04-13

该综述检索Pubmed和Cochrane数据库截至2023年2月的文献,探讨炎症性肠病患者肌肉减少症的发病机制、评估工具与临床影响。肌肉减少症影响高达50%的炎症性肠病患者,与住院增加、需手术及术后并发症等不良结局相关,且独立于炎症性肠病活动度。作者认为应在所有炎症性肠病患者中定期评估肌肉健康状况。

要点

  • 肌肉减少症影响高达50%的炎症性肠病患者,与住院增加、需手术及术后并发症相关。
  • 传统评估依赖横断面影像直接测量,但存在时间、成本和辐射暴露问题。
  • 握力、上臂中围、生物电阻抗分析及床旁超声等新工具可用于评估肌肉。

核心结论

  • 肌肉减少症与不良临床结局相关,且独立于炎症性肠病活动度。
  • 作者认为应在所有炎症性肠病患者中定期评估肌肉健康状况。
  • 未来研究需更好地理解病理生理及最有效的肌肉减少症管理,以指导临床照护并减少疾病相关并发症。

研究设计与样本

  • 综述文章,检索Pubmed和Cochrane数据库截至2023年2月发表的文献。
  • 检索关键词包括「炎症性肠病」「克罗恩病」「溃疡性结肠炎」「肌肉减少症」「肌脂肪变性」「肌肉健康」和「衰弱」。

主要发现

  • 肌肉减少症影响高达50%的炎症性肠病患者。
  • 发病机制尚未明确,但有证据支持吸收不良、蛋白质摄入减少、慢性炎症、菌群失调、体力活动减少、药物效应及内脏脂肪的激素信号等作用。
  • 传统评估技术包括横断面影像直接测量,但存在时间、成本和辐射暴露问题。
  • 新的床旁工具可估计肌肉量,包括握力、上臂中围和生物电阻抗分析评估身体成分。
  • 已提出评估肌肉量的新型生物标志物及床旁超声技术,使炎症性肠病门诊的肌肉减少症评估更简化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia, a loss of skeletal muscle mass or function, affects up to 50% of patients with inflammatory bowel disease (IBD) and is associated with poor clinical outcomes including increased hospitalizations, need for surgery and post-operative complications. Despite the high prevalence and clinical significance of sarcopenia in patients with IBD, few patients undergo routine muscle evaluation. AIM: The goal of this study was to review the mechanisms of sarcopenia in patients with IBD and understand novel modalities to assess and treat impaired muscle mass or function. METHODS: Pubmed and Cochrane databases were searched including articles published up to February 2023 utilizing the following keywords: "inflammatory bowel disease", "IBD", "Crohn's disease", "ulcerative colitis", "sarcopenia", "myosteatosis", "muscle health", and "frailty". RESULTS: The pathogenesis of sarcopenia in IBD is not well defined, however, there is evidence supporting the role of malabsorption, reduced protein intake, chronic inflammation, dysbiosis, decreased physical activity, medication effects and hormone signaling from visceral adiposity. Traditional sarcopenia assessment techniques include direct measurements on cross sectional imaging. However, given the time, cost and radiation exposure associated with cross sectional imaging, new bedside tools are now available to estimate muscle mass, including assessment of grip strength, mid upper arm circumference and body composition utilizing bioelectrical impedance analysis. In addition, novel biomarkers for assessing muscle mass and techniques utilizing point of care ultrasound have been proposed to make sarcopenia evaluation more streamlined in the IBD clinic. CONCLUSION: Sarcopenia is associated with poor clinical outcomes independent of IBD activity and therefore muscle health should be assessed in all IBD patients at routine intervals. Future studies to better our understanding of the pathophysiology as well as most effective management of sarcopenia in IBD will help guide clinical care and reduce disease related complications.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Gold SL, Raman M, Sands BE, et al. Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 37051722. doi:10.1111/apt.17498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。